Search

Your search keyword '"Foddis R"' showing total 25 results

Search Constraints

Start Over You searched for: Author "Foddis R" Remove constraint Author: "Foddis R" Topic mesothelioma Remove constraint Topic: mesothelioma
25 results on '"Foddis R"'

Search Results

1. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.

2. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

3. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.

4. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.

5. A Novel Panel of Serum Biomarkers for MPM Diagnosis.

6. Expression status of candidate genes in mesothelioma tissues and cell lines.

7. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.

8. Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.

9. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

10. [Identification and characterization of microRNA involving in malignant pleural mesothelioma].

11. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.

12. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.

13. Soluble markers for diagnosis of malignant pleural mesothelioma.

14. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.

15. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.

16. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.

17. [Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma].

18. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study.

19. [SV40: a possible co-carcinogen of asbestos in the pathogenesis of mesothelioma?].

20. SV40 infection induces telomerase activity in human mesothelial cells.

21. SV40 and the pathogenesis of mesothelioma.

22. SV40 can be reproducibly detected in paraffin-embedded mesothelioma samples.

23. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma

24. Studio preliminare volto all'inquadramento del significato preventivo del dosaggio di frazioni di GGT in una popolazione di lavoratori ex-esposti ad Amianto.

25. A Novel Panel of Serum Biomarkers for MPM Diagnosis

Catalog

Books, media, physical & digital resources